DelveInsight’s “Autosomal Dominant Polycystic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Autosomal Dominant Polycystic Kidney Disease, historical and forecasted epidemiology as well as the Autosomal Dominant Polycystic Kidney Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Autosomal Dominant Polycystic Kidney Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Autosomal Dominant Polycystic Kidney Disease Market Forecast

Some of the key facts of the Autosomal Dominant Polycystic Kidney Disease Market Report: 

• The Autosomal Dominant Polycystic Kidney Disease market size was valued approximately USD 1,365 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In 2022, the total diagnosed prevalent cases of ADPKD across the 7MM were approximately 368,479. These identified prevalent instances of ADPKD are anticipated to rise by 2032.
• DelveInsight anticipates that in 2022, there were roughly 143,708 diagnosed prevalent cases of ADPKD in the US. Approximately 193,718 cases were diagnosed as prevalent cases in the UK and EU4. By 2032, these figures are anticipated to rise.
• The evolving ADPKD pipeline comprises several candidates like Tesevatinib/KD019, Bardoxolone methyl, GLPG2737, JNJ-0237/AT-20494, RGLS8429, and XRx-008. Some of these medications are anticipated to be introduced within the forecasted duration (2023-2032).
• Key Autosomal Dominant Polycystic Kidney Disease Companies: XORTX Therapeutics, Sanofi, Galapagos NV, Janssen Pharmaceuticals, Regulus Therapeutics, Reata Pharmaceuticals, Otsuka Pharmaceutical, Palladio Biosciences, Kadmon, Novartis, Pfizer, and others
• Key Autosomal Dominant Polycystic Kidney Disease Therapies: XRx-008, Tesevatinib/KD019, GLPG2737, JNJ-0237/AT-20494, RGLS8429, Bardoxolone methyl, AT-20494, Tolvaptan, Lixivaptan, Tesevatinib, Everolimus, Rapamune, Tolvaptan (OPC-41061), and others
• The ADPKD epidemiology based on gender analyzed that the mutation-specific distribution of the disease suggests a higher prevalence of ADPKD due to mutation in PKD1 gene than in PKD2 gene.
• The Autosomal Dominant Polycystic Kidney Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Autosomal Dominant Polycystic Kidney Disease pipeline products will significantly revolutionize the Autosomal Dominant Polycystic Kidney Disease market dynamics.

Autosomal Dominant Polycystic Kidney Disease Overview

Mutations in two genes, PKD1 (16p13.3) and PKD2 (4q21), are the primary cause of ADPKD. Approximately 85% of instances in mutation-specific ADPKD cases are of the PKD1 gene, with the remaining cases being of the PKD2 gene, according to various country-specific organizations.

Get a Free sample for the Autosomal Dominant Polycystic Kidney Disease Market Report 

https://www.delveinsight.com/report-store/autosomal-dominant-polycystic-kidney-disease-market

Autosomal Dominant Polycystic Kidney Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Autosomal Dominant Polycystic Kidney Disease Epidemiology Segmentation:

The Autosomal Dominant Polycystic Kidney Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Autosomal Dominant Polycystic Kidney Disease
• Prevalent Cases of Autosomal Dominant Polycystic Kidney Disease by severity
• Gender-specific Prevalence of Autosomal Dominant Polycystic Kidney Disease
• Diagnosed Cases of Episodic and Chronic Autosomal Dominant Polycystic Kidney Disease

Download the report to understand which factors are driving Autosomal Dominant Polycystic Kidney Disease epidemiology trends @ Autosomal Dominant Polycystic Kidney Disease Epidemiology Forecast

Autosomal Dominant Polycystic Kidney Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Autosomal Dominant Polycystic Kidney Disease market or expected to get launched during the study period. The analysis covers Autosomal Dominant Polycystic Kidney Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Autosomal Dominant Polycystic Kidney Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Autosomal Dominant Polycystic Kidney Disease Therapies and Key Companies

• XRx-008: XORTX Therapeutics
• Tesevatinib/KD019: Sanofi
• GLPG2737: Galapagos NV
• JNJ-0237/AT-20494: Janssen Pharmaceuticals
• RGLS8429: Regulus Therapeutics
• Bardoxolone methyl: Reata Pharmaceuticals
• AT-20494: Janssen Pharmaceuticals
• Tolvaptan: Otsuka Pharmaceutical
• Lixivaptan: Palladio Biosciences
• Tesevatinib: Kadmon
• Everolimus: Novartis
• Rapamune: Pfizer
• Tolvaptan (OPC-41061): Otsuka Pharmaceutical

Discover more about therapies set to grab major Autosomal Dominant Polycystic Kidney Disease market share @ ADPKD Treatment Market

Autosomal Dominant Polycystic Kidney Disease Market Strengths

• Technological advances in diagnostic procedures due to an increasing focus on early diagnosis has reduced undiagnosed cases, thus persistent rising cases of diagnosed ADPKD offer opportunities to companies to launch new therapies in the market.
• Advances are being made in unraveling the genetic origins of ADPKD, in non-invasive monitoring and in predicting disease progression that will help in better disease management.

Autosomal Dominant Polycystic Kidney Disease Market Opportunities

• Pre-symptomatic diagnosis and their application in the care and management of individuals at risk for ADPKD.
• Identification of biomarkers for early detection of ADPKD patients at high risk for progression will help better manage ADPKD patients and prevent their progression.

Scope of the Autosomal Dominant Polycystic Kidney Disease Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Autosomal Dominant Polycystic Kidney Disease Companies: XORTX Therapeutics, Sanofi, Galapagos NV, Janssen Pharmaceuticals, Regulus Therapeutics, Reata Pharmaceuticals, Otsuka Pharmaceutical, Palladio Biosciences, Kadmon, Novartis, Pfizer, and others
• Key Autosomal Dominant Polycystic Kidney Disease Therapies: XRx-008, Tesevatinib/KD019, GLPG2737, JNJ-0237/AT-20494, RGLS8429, Bardoxolone methyl, AT-20494, Tolvaptan, Lixivaptan, Tesevatinib, Everolimus, Rapamune, Tolvaptan (OPC-41061), and others
• Autosomal Dominant Polycystic Kidney Disease Therapeutic Assessment: Autosomal Dominant Polycystic Kidney Disease current marketed and Autosomal Dominant Polycystic Kidney Disease emerging therapies
• Autosomal Dominant Polycystic Kidney Disease Market Dynamics: Autosomal Dominant Polycystic Kidney Disease market drivers and Autosomal Dominant Polycystic Kidney Disease market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Autosomal Dominant Polycystic Kidney Disease Unmet Needs, KOL’s views, Analyst’s views, Autosomal Dominant Polycystic Kidney Disease Market Access and Reimbursement 

To know more about Autosomal Dominant Polycystic Kidney Disease companies working in the treatment market, visit @ ADPKD Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Autosomal Dominant Polycystic Kidney Disease Market Report Introduction

2. Executive Summary for Autosomal Dominant Polycystic Kidney Disease

3. SWOT analysis of Autosomal Dominant Polycystic Kidney Disease

4. Autosomal Dominant Polycystic Kidney Disease Patient Share (%) Overview at a Glance

5. Autosomal Dominant Polycystic Kidney Disease Market Overview at a Glance

6. Autosomal Dominant Polycystic Kidney Disease Disease Background and Overview

7. Autosomal Dominant Polycystic Kidney Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Autosomal Dominant Polycystic Kidney Disease 

9. Autosomal Dominant Polycystic Kidney Disease Current Treatment and Medical Practices

10. Autosomal Dominant Polycystic Kidney Disease Unmet Needs

11. Autosomal Dominant Polycystic Kidney Disease Emerging Therapies

12. Autosomal Dominant Polycystic Kidney Disease Market Outlook

13. Country-Wise Autosomal Dominant Polycystic Kidney Disease Market Analysis (2019–2032)

14. Autosomal Dominant Polycystic Kidney Disease Market Access and Reimbursement of Therapies

15. Autosomal Dominant Polycystic Kidney Disease Market Drivers

16. Autosomal Dominant Polycystic Kidney Disease Market Barriers

17.  Autosomal Dominant Polycystic Kidney Disease Appendix

18. Autosomal Dominant Polycystic Kidney Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services